ABSTRACT
Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.
- Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
Clicking the link below will connect you to begin the credit-claiming process for CME and MOC. After clicking on the link, scroll to the bottom of the page and click on “Complete the CME/MOC Process.” You will need your myCME login information to access this.
- Rahul Jaswaney, MD
- Samantha Sokoloff, MD
- Val Rakita, MD
- Daniel J. Rubin, MD, MSc⇑
- Professor of Medicine, Interim Co-Director for the Center for Biostatistics and Epidemiology, Director of Clinical Research, and Deputy Chief, Section of Endocrinology, Diabetes and Metabolism, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
- Address:
Daniel J. Rubin, MD, MSc, Lewis Katz School of Medicine at Temple University, Medical Office Building 3322 N. Broad Street, Suite 205, Philadelphia, PA 19140; Daniel.rubin{at}tuhs.temple.edu
ABSTRACT
Despite current therapies, heart failure and chronic kidney disease continue to be major causes of morbidity and mortality. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors have recently become standard-of-care therapy for these conditions. This review summarizes important randomized controlled trials of SGLT-2 inhibitors and guidelines for using these agents in patients with heart failure and chronic kidney disease in both clinic and hospital settings.
- Copyright © 2024 The Cleveland Clinic Foundation. All Rights Reserved.
